Clinical trial Recruiting at 1 site Observational Ages 18 and up

Biomarker-guided care for mild traumatic brain injury using GFAP and UCH-L1

Official title: BLOOD BIOMARKERS TO IMPROVE MANAGEMENT OF MILD TRAUMATIC BRAIN INJURY IMPLIMENTACIÓN STUDY

Run by Hospital Universitario 12 de Octubre · NCT07311486 · Data updated 2026-11-12

This project will try a blood test that measures GFAP and UCH-L1 to see if adults with recent mild traumatic brain injury can safely avoid a head CT.

More Mild Traumatic Brain Injury trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorHospital Universitario 12 de Octubre
Academic / other
Locations1 site (Madrid, Madrid)
StatusRecruiting
StartedJuly 15, 2025
Main results expectedMay 1, 2026
Study endsMay 1, 2026
Registry record updatedDecember 31, 2025
Trial IDNCT07311486 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (age 18+) who present to the ER within 12 hours of a plausible head injury with GCS 13–15 and clinical signs or symptoms of mild TBI, and who can provide a blood sample before imaging.

Probably not a fit

Patients with moderate or severe TBI (GCS ≤12), children, those with unknown or >12-hour time since injury, or those needing immediate imaging are unlikely to benefit from this pathway.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This ambispective cohort study at Hospital Universitario 12 de Octubre implements a clinical pathway using the VIDAS TBI blood assay (GFAP and UCH-L1) within 12 hours of injury to guide CT decisions for mild TBI. Patients managed under the new biomarker-based pathway will be compared to a historical six-month cohort treated before the pathway was introduced. Key outcomes are diagnostic performance for ruling out CT need, safety (missed intracranial injuries or neurological deterioration), and operational impact such as CT use and emergency department length of stay. Blood samples are obtained before imaging and predefined biomarker thresholds are applied as part of routine ER care.

Why it matters

Potential benefit: If successful, it could safely reduce unnecessary head CT scans and shorten emergency department stays for people with mild TBI.

How similar studies have gone: Previous work using GFAP and UCH-L1 has shown promise and supported regulatory clearance of similar biomarker tests, though real-world implementation in ER pathways remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* -All adult patients suffering mild TBI:( Defined by at least criterion a) and d) and one or more of the other criteria)

  1. The presence of a plausible traumatic mechanism observed/or related by the patient´s recount of the injury event.
  2. Presence of one or more clinical signs attributable to brain injury: Loss of consciousness immediately following injury, alteration of mental status immediately following the injury, posttraumatic amnesia or any neurological abnormality.
  3. At least two acute symptoms related to the injury: feeling confused or disoriented, headache, nausea, vomiting, dizziness, vision problems, memory problems, emotional lability or irritability.
  4. a GCS between 15 and 13, at least 30 minutes after injury.
* Blood sample obtained ≤12 h after injury and ideally before any imaging prescription.

Exclusion Criteria:

* · GCS 3-12 on admission

  * Age Below 18 years
  * Time of injury unknown
  * Time to injury exceeding 12 hours
  * Primary admission for non-traumatic neurological disorder (e.g., stroke, spontaneous, intracranial hematoma)
  * Penetrating head trauma
  * Patient with mechanical ventilation from the trauma scene or prehospital management
  * Venipuncture not feasible

Where it's running

  • Hospital Universitario 12 de Octubre
    Madrid, Madrid, Spain
    Recruiting

Study contacts

  • Principal investigator: Alfonso Lagares, MD, PhD — Hospital Universitario 12 de Octubre
  • Study coordinator: Alfonso Lagares, MD, PhD
  • Email: alfonlag@ucm.es
  • Phone: +34913908000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.